CA2989722C - Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy - Google Patents

Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy Download PDF

Info

Publication number
CA2989722C
CA2989722C CA2989722A CA2989722A CA2989722C CA 2989722 C CA2989722 C CA 2989722C CA 2989722 A CA2989722 A CA 2989722A CA 2989722 A CA2989722 A CA 2989722A CA 2989722 C CA2989722 C CA 2989722C
Authority
CA
Canada
Prior art keywords
triazin
dimethyl
pyrazolo
amine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989722A
Other languages
English (en)
French (fr)
Other versions
CA2989722A1 (en
Inventor
Jacob Westman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curovir AB
Original Assignee
Curovir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curovir AB filed Critical Curovir AB
Publication of CA2989722A1 publication Critical patent/CA2989722A1/en
Application granted granted Critical
Publication of CA2989722C publication Critical patent/CA2989722C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2989722A 2015-06-24 2016-06-10 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy Active CA2989722C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173687.3 2015-06-24
EP15173687 2015-06-24
PCT/EP2016/063383 WO2016206999A1 (en) 2015-06-24 2016-06-10 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy

Publications (2)

Publication Number Publication Date
CA2989722A1 CA2989722A1 (en) 2016-12-29
CA2989722C true CA2989722C (en) 2023-09-19

Family

ID=53483747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989722A Active CA2989722C (en) 2015-06-24 2016-06-10 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy

Country Status (10)

Country Link
US (1) US10407429B2 (enExample)
EP (1) EP3313842B1 (enExample)
JP (1) JP6689299B2 (enExample)
CN (1) CN107949563B (enExample)
AU (1) AU2016284638B2 (enExample)
BR (1) BR112017026061B1 (enExample)
CA (1) CA2989722C (enExample)
RU (1) RU2712196C2 (enExample)
WO (1) WO2016206999A1 (enExample)
ZA (1) ZA201800485B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3010661T3 (en) 2016-02-26 2025-04-04 Univ Leland Stanford Junior Pi-kinase inhibitors with anti-infective activity
PL3606926T3 (pl) * 2017-04-05 2021-11-02 Curovir Ab Heteroaromatyczne związki użyteczne w terapii
JP7133023B2 (ja) * 2018-01-17 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｐｉ４ｋｉｉｉベータ阻害剤
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
EP3864017B1 (en) * 2018-10-10 2023-07-26 Curovir Ab 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
EP3908577A4 (en) * 2019-01-11 2022-06-29 The Board of Trustees of the Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
CA3134417A1 (en) 2019-03-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors and methods of using the same
WO2021032611A1 (en) 2019-08-20 2021-02-25 Curovir Ab Heteroaromatic compounds useful in therapy
CN113801119B (zh) * 2021-08-30 2022-09-30 新乡医学院 一种吡唑并[1,3,5]三嗪类化合物的合成方法
WO2024184442A1 (en) 2023-03-09 2024-09-12 Curovir Ab Compound and formulation for systemic therapy by oral transmucosal administration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) * 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
IL137019A0 (en) * 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
PL354675A1 (en) * 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2920181B1 (en) * 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds

Also Published As

Publication number Publication date
RU2018102449A3 (enExample) 2019-08-20
BR112017026061A2 (pt) 2018-08-14
US10407429B2 (en) 2019-09-10
NZ738280A (en) 2024-10-25
JP2018522861A (ja) 2018-08-16
JP6689299B2 (ja) 2020-04-28
WO2016206999A1 (en) 2016-12-29
RU2018102449A (ru) 2019-07-24
EP3313842A1 (en) 2018-05-02
CN107949563B (zh) 2020-06-05
ZA201800485B (en) 2020-05-27
RU2712196C2 (ru) 2020-01-24
AU2016284638B2 (en) 2020-01-23
HK1254809A1 (en) 2019-07-26
CA2989722A1 (en) 2016-12-29
BR112017026061B1 (pt) 2023-03-28
EP3313842B1 (en) 2020-04-15
CN107949563A (zh) 2018-04-20
US20180298007A1 (en) 2018-10-18
AU2016284638A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
AU2016284638B2 (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
JP7369458B2 (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４－オキサジアゾール誘導体
CA2935658C (en) Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy
JP7217752B2 (ja) Ａｃｓｓ２阻害剤およびその使用方法
JP7200126B2 (ja) 療法において有用なヘテロ芳香族化合物
KR102092207B1 (ko) 항바이러스 활성을 가진 메탄티온 화합물
HK1254809B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
BR112019019796B1 (pt) Composto, composição farmacêutica, e, uso de composto ou de sal farmaceuticamente aceitável
HK40019049B (en) Heteroaromatic compounds useful in therapy
HK40019049A (en) Heteroaromatic compounds useful in therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210512

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260722